Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. The company operates in two segments, Orphan and Inflammation. Its portfolio comprises 12 medicines in the areas of rare diseases, gout, ophthalmology, and inflammation. It markets TEPEZZA (teprotumumab-trbw) for intravenous infusion; KRYSTEXXA (pegloticase injection) for intravenous infusion; RAVICTI (glycerol phenylbutyrate) oral liquid; PROCYSBI (cysteamine bitartrate) delayed-release capsules and granules for oral use; ACTIMMUNE (interferon gamma-1b) injection for subcutaneous use; BUPHENYL (sodium phenylbutyrate) tablets and powder for oral use; QUINSAIR (levofloxacin) solution for inhalation; and UPLIZNA (inebilizumab-cdon) injection for intravenous use. The company also markets PENNSAID (diclofenac sodium topical solution) for topical use; DUEXIS (ibuprofen/famotidine) tablets for oral use; RAYOS (prednisone) delayed-release tablets for oral use; and VIMOVO (naproxen/esomeprazole magnesium) delayed-release tablets for oral use. It has collaboration agreements with HemoShear Therapeutics, LLC.; Alpine Immune Sciences, Inc.; Halozyme Therapeutics, Inc.; and Arrowhead Pharmaceuticals, Inc. The company was formerly known as Horizon Pharma Public Limited Company and changed its name to Horizon Therapeutics Public Limited Company in May 2019. Horizon Therapeutics Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland with additional offices in Deerfield, Illinois; Chicago, Illinois; Lake Forest, Illinois; South San Francisco, California; Washington, D.C.; Gaithersburg, Maryland; Rockville, Maryland; and Mannheim, Germany.

Zāļu ražotāji - vispārīgi

Mr. Patrick  McIlvenny

Senior Vice President & Chief Accounting Officer

Ms. Tina E. Ventura

Senior Vice President & Chief Investor Relations Officer

Mr. Timothy P. Walbert

Chairman, Pres & Chief Executive Officer

Ms. Keli  Walbert

Executive Vice President & Chief Marketing Officer

Mr. Geoffrey M. Curtis

Executive Vice President of Corporation Affairs & Chief Communications Officer

Mr. Sean M. Clayton J.D.

Executive Vice President & Gen. Counsel

Dr. Jeffrey W. Sherman F.A.C.P., FACP, M.D.

Executive Vice President & Chief Medical Officer

Mr. Aaron L. Cox

Executive Vice President of Fin. & Chief Financial Officer

Ms. Jane  Gonnerman

Senior Vice President of Corporation Devel. & Chief of Staff, Office of the Chief Executive Officer

Nosaukums	Tirgus kapitalizācija
Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd.	0M
PT Kalbe Farma Tbk.	0M
Otsuka Holdings Co., Ltd.	0M
Merck & Co., Inc.	0M
Amgen Inc.	0M
Hunan Jingfeng Pharmaceutical Co.,Ltd.	0M
JCR Pharmaceuticals Co., Ltd.	0M
Bristol-Myers Squibb Company	0M
GSK plc	0M
Luye Pharma Group Ltd.	0M
Mayne Pharma Group Limited	0M

Horizon Therapeutics Public Limited Company

Horizon Therapeutics Public Limited Company Konkurentu saraksts

Galvenie konkurenti